1 / 19

Angioedema in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT

AbstractALLHAT, the largest antihypertensive study conducted to date, randomized 42,418 participants to one of four antihypertensive drug classes/drugs (diuretic/chlorthalidone, calcium-channel blocker/amlodipine, angiotensin-converting enzyme (ACE) inhibitor/lisinopril, and alpha-blocker/doxazosi

lynde
Download Presentation

Angioedema in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Angioedema in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)* Linda Piller*, Charles Ford, Barry Davis, Chuke Nwachuku, Henry Black, Suzanne Oparil, Saib Gappy, Tamrat Retta, Jeffrey Probstfield for the ALLHAT Collaborative Research Group Sponsored by the National Heart, Lung, and Blood Institute (NHLBI) *The University of Texas School of Public Health Houston, Texas

More Related